Marking a new milestone for artificial intelligence (AI) adoption in the breast screening community across the Island of Ireland, United Kingdom-based Kheiron Medical Technologies has engaged with Hospital Services Limited (HSL) to bring the Mia® solution to the Health Services in Northern Ireland and the Republic of Ireland. As the first and only solution of its kind with CE regulatory clearance for use as an AI-enabled independent reader for the early detection of breast cancer, Mia is being launched in partnership with specialist medical supplies distributor HSL, an Island-of-Ireland based company focused on bringing market-leading healthcare technology products and solutions to public and private hospitals in the UK and Ireland.
“Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools,” states Alex Hamlow, Kheiron’s Chief Commercial Officer. “We’re excited that Mia is the first AI independent reader solution available for use within the breast screening community across the Island of Ireland. Based on its performance in the UK and Europe, Mia represents a major breakthrough in helping radiologists to dramatically improve breast cancer detection and patient outcomes.”
“According to Breast Cancer Ireland, 690 deaths are attributed to breast cancer annually in the Republic of Ireland and 3,700 women in Ireland are diagnosed every year with breast cancer. In our meetings with radiologists and breast screening programme leaders across Ireland, we’ve had the opportunity to discuss how AI and Mia can help both radiologists and the women they care for,” Mr Hamlow continued.
With patented AI technology developed on more than three million breast images, Mia (Mammography Intelligent Assessment) is designed to support breast radiologists in deciding whether to recall women for further testing based on their mammography screening. It was created to deliver gold standard double-reading quality with a single human reader and can also function as an independent second reader, a concurrent reader, or in double reader triage.
“We are looking forward to bringing the Mia solution to the breast screening community throughout Ireland,” comments Dominic Walsh, HSL’s Chief Executive Officer. “It has tremendous potential to transform the breast screening pathway by empowering breast screening professionals to detect potential malignancies more accurately and quickly, ultimately saving more lives in the fight against breast cancer.”
Mia’s effectiveness has been proven in one of the most ambitious clinical studies in radiology AI to date, which evaluated Mia as an independent reader of mammograms and as a triaging solution. This ground-breaking study tested Mia across more than 275,000 cases from seven sites in the UK and Hungary. In addition, Kheiron was one of the recipients of the UK Government’s first AI in Health and Care Awards through which Mia is undergoing multiple deployments and clinical studies across 15 sites as a benchmark for how to integrate new, cutting-edge technologies into the NHS safely and effectively.
PR
21st March 2024
“It’s a lifesaver, it’s a life changer,” says one of the first women in the UK to have her breast cancer picked up by Kheiron Medical’s technology called Mia® An artific...
Read moreAbstract
4th January 2023
Purpose To demonstrate real-world post-market benefit of artificial intelligence (AI) as an extra reader in breast cancer screening (BCS). Method A commercially available AI system...
Read moreAbstract
4th January 2023
Purpose To evaluate the effectiveness and practical implications of a novel workflow of using AI as a supporting reader for the detection of breast cancer in double reading screeni...
Read moreAbstract
4th January 2023
Purpose To demonstrate the importance of using representative data, including unconfirmed cases (neither positive nor negative) to assess recall rate (RR) and avoid obscuring real-...
Read morePR
28th November 2022
NHS Grampian, which provides health and social care services to more than 500,000 people in Scotland, is trialling Kheiron Medical Technologies’ artificial intelligence to help ...
Read morePR
28th November 2022
In October 2021, Gateshead Health Foundation NHS Trust entered into a research agreement with Kheiron Medical Technologies as part of the NHS Artificial Intelligence (AI) in Health...
Read morePR
11th May 2022
Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel are trailblazers at the forefront of introducing innovative breast imaging technologies into clinical practice (London ...
Read morePR
4th May 2022
InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in...
Read morePR
9th March 2022
This AI cancer diagnostics company joins the ranks of Canva, Microsoft, SpaceX, and other winning companies that are changing lives for the better (London – March 9, 20...
Read more